Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review

    January 2020 in “Postepy Dermatologii I Alergologii
    Kornelia Pietrauszka, Beata Bergler-Czop
    Image of study
    TLDR Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.
    A review article from 2020 suggests that measuring sulfotransferase SULT1A1 activity in hair follicles can predict the response to minoxidil treatment in patients with androgenetic alopecia. This potential prognostic marker could be useful in predicting treatment effectiveness, but more research is needed to confirm its validity. The document also reviews other treatments for androgenetic alopecia, including finasteride, dutasteride, spironolactone, platelet-rich plasma, microneedling, and light/laser therapy. Topical minoxidil and oral finasteride are currently the only FDA-approved treatments for the condition.
    View this study on →

    Cited in this study